Showing results for "Myovant Sciences"
markets
Sumitomo Unit Agrees to Buy Myovant After Increasing OfferA fully-owned subsidiary of Sumitomo Pharma Co. agreed to buy the rest of drugmaker Myovant Sciences Ltd. for $1.7 billion after raising its offer, as it seeks to bolster the development of medicines for women’s health and prostate cancer.October 24, 2022
business
Meet Five of Wall Street’s Top Cannabis Investment BankersHi, Crystal Tse here in New York. Welcome to the Bloomberg Deals newsletter. Today I’m profiling five of the top cannabis bankers on Wall Street on how they work within the regulation around the space. We also have a fresh SPAC deal from a high-profile former bank executive and some exclusive VC rounds. Today's top storiesOctober 3, 2022
markets
Sumitomo Offers to Buy All of Myovant in Deal Worth $2.5 BillionA fully-owned subsidiary of Sumitomo Pharma Co. offered to buy the remaining outstanding shares of pharmaceutical company Myovant Sciences Ltd., seeking to bolster the development of drugs for women’s health and prostate cancer.October 2, 2022